Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,652 shares of the biopharmaceutical company’s stock after selling 5,236 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.06% of Alnylam Pharmaceuticals worth $36,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. Root Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $25,000. Salomon & Ludwin LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. ORG Partners LLC increased its holdings in Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 33 shares during the period. Quent Capital LLC purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Hilltop National Bank acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $41,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 9,577 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This trade represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 36,578 shares of company stock worth $12,416,105. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ALNY shares. Barclays began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective on the stock. Truist Financial cut their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 target price on the stock. Finally, Chardan Capital dropped their target price on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and reaffirmed a “buy” rating, citing upside vs. the current price (Canaccord’s note implies meaningful upside). Canaccord price-target raise
• Positive Sentiment: A MarketBeat-linked Motley Fool piece reports a pundit upgrade that helped lift sentiment and trading interest in ALNY. Why Alnylam Was Soaring
• Positive Sentiment: A bullish roundup in The Globe and Mail highlighted Alnylam among favorable healthcare ideas, supporting broader analyst-driven positivity. Analysts Are Bullish
• Neutral Sentiment: Short-interest data in the feed shows zero/NaN values and a 0.0 days-to-cover figure — likely a data/reporting artifact rather than new market pressure; treat as non-actionable until confirmed by an exchange report.
• Negative Sentiment: Multiple insider sales disclosed this week could weigh on sentiment: CEO Yvonne Greenstreet sold 6,958 shares at ~$310; several EVPs (Jeffrey Poulton, Kevin Fitzgerald, Tolga Tanguler, Pushkal Garg) sold mid‑hundreds to low‑thousands of shares at ~$310–332. These trades reduced insiders’ stakes by mid-single-digit percentages. Filings: SEC links for the disclosures. Yvonne Greenstreet SEC filing Jeffrey Poulton SEC filing Kevin Fitzgerald filings Tolga Tanguler SEC filing Pushkal Garg SEC filing
• Negative Sentiment: Chardan Capital trimmed its price target to $425 (from a higher prior target), a modest negative datapoint that partly offsets other analyst optimism. Chardan target cut

Alnylam Pharmaceuticals Trading Up 5.8%

Shares of NASDAQ:ALNY opened at $332.61 on Wednesday. The business’s 50 day moving average price is $371.01 and its 200-day moving average price is $424.25. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The firm has a market capitalization of $44.11 billion, a price-to-earnings ratio of 194.51 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.65) EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.